All In Biotech

Drug Trial Radar · NCT05818943

Honeycomb: Evaluation of Radiprodil in Children with GRIN-related Disorder

A Multicenter Study to Assess the Safety, Tolerability, Pharmacokinetics, and Effect on Seizures and Behavioral Symptoms of Multiple Individually Titrated Doses of Radiprodil in Children with GRIN-related Disorder

Last checked: Nov 19, 2026Latest source record: Nov 15, 2024 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruiting

Status

Active, not recruiting

Enrollment

24

Planned (sponsor's estimate)

Start

Mar 7, 2023

Primary completion

Nov 2026

Study completion Nov 2026

Sponsor

Lead sponsor
GRIN Therapeutics, Inc.Industry
Sponsor type
Industry
First posted
Apr 19, 2023

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 6 months, up to 12 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Study RAD-GRIN-101 is a phase 1B trial to assess safety, tolerability, PK, and potential efficacy of radiprodil for the treatment of GRIN-related disorder in children with a Gain-of-Function (GoF) genetic variant. The study is open-label, so all participants will be treated with radiprodil. Subjects' participation in the study is expected to last up to six months in Part A. After the end of part A, all participants who are still eligible can choose to continue to receive radiprodil as part of an open-label long-term treatment period (Part B).

Conditions

  • GRIN-related Disorders

Interventions

  • RadiprodilDrug

    Radiprodil is an orally active, negative allosteric modulator of the NR2B subunit of the NMDA receptor.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Incidence of Treatment-Emergent Adverse Events (TEAEs), Serious TEAEs (SAEs), TEAEs Leading to Discontinuation and Severity of TEAEsTime frame: through study completion (average of 2 years).
  2. Maximum Plasma concentration of radiprodil (Cmax)Time frame: Titration Visit 1 (week 5): 0,1,2,4,6,8,10,12 hours post-dose. Titration Visits 2,3,4 (week 6 to 11) and Maintenance Visit 4 (week 20): 0,1,2,5 hours post-dose.
  3. Pharmacokinetic plasma concentration of radiprodil: half-life (T1/2)Time frame: Titration Visit 1 (week 5): 0,1,2,4,6,8,10,12 hours post-dose. Titration Visits 2,3,4 (week 6 to 11) and Maintenance Visit 4 (week 20): 0,1,2,5 hours post-dose.
  4. Plasma concentration of radiprodil versus time, area under the curve (AUCt)Time frame: Titration Visit 1 (week 5): 0,1,2,4,6,8,10,12 hours post-dose. Titration Visits 2,3,4 (week 6 to 11) and Maintenance Visit 4 (week 20): 0,1,2,5 hours post-dose.
  5. Pharmacokinetic plasma concentration of radiprodil, clearance (Cl)Time frame: Titration Visit 1 (week 5): 0,1,2,4,6,8,10,12 hours post-dose. Titration Visits 2,3,4 (week 6 to 11) and Maintenance Visit 4 (week 20): 0,1,2,5 hours post-dose.
  6. Pharmacokinetic plasma concentration of radiprodil, Time corresponding to occurrence of Cmax (Tmax)Time frame: Titration Visit 1 (week 5): 0,1,2,4,6,8,10,12 hours post-dose. Titration Visits 2,3,4 (week 6 to 11) and Maintenance Visit 4 (week 20): 0,1,2,5 hours post-dose.

Locations

15 sites in 8 countries. Site status is shown where the registry gives one.

  • Mid-Atlantic Epilepsy and Sleep Center

    Bethesda, Maryland

  • Columbia University Irving Medical Center, Dept of Neurology

    New York, New York

  • Queensland Children's Hospital

    South Brisbane, Queensland, Australia

  • BC Children's Hospital

    Vancouver, Canada

  • The Hospital for Sick Children (Sick Kids)

    Toronto, Ontario, Canada

  • Abteilung für Neuropädiatrie, Klinik und Poliklinik für Kinder - und Jugendmedizin, Universitätsklinikum Leipzig

    Leipzig, Germany

  • KBO-Kinderzentrum München gemeinnützige GmbH

    München, Germany

  • Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS) - Ospedale Pediatrico Bambino Gesu

    Rome, Lazio, Italy

  • Azienda Ospedaliero Universitaria Careggi (AOUC) Firenze - Azienda Ospedaliera Universitaria Meyer

    Florence, Tuscany, Italy

  • ERASMUS Medisch Centrum, Developmental & Genetic pediatrics

    Rotterdam, Netherlands

  • UMC Utrecht - Wilhelmina Kinderziekenhuis, Polikliniek Kinderneurologie

    Utrecht, Netherlands

  • Universitat de Barcelona - Hospital Sant Joan de Deu Barcelona (HSJDB)

    Barcelona, Spain

  • Hospital Ruber Internacional

    Madrid, Spain

  • Royal Hospital for Children Glasgow

    Glasgow, United Kingdom

  • Great Ormond Street Hospital For Children NHS Foundation Trust

    London, United Kingdom

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.